Cargando…

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma

BACKGROUND: The role of tumor necrosis factor alpha (TNF-α) in targeted therapy for hepatocellular carcinoma (HCC) remains largely unknown. The current study aimed to clarify the mechanistic effects of targeting TNF-α to overcome sorafenib resistance in HCC. METHODS: A correlation of TNF-α expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Wenliang, Luo, Xuan, Li, Wenda, Zhong, Jinyi, Cao, Jun, Zhu, Sicong, Chen, Xianqing, Zhou, Rui, Shang, Changzhen, Chen, Yajin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412090/ https://www.ncbi.nlm.nih.gov/pubmed/30594557 http://dx.doi.org/10.1016/j.ebiom.2018.12.047

Ejemplares similares

Corrigendum to “TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma” [EBioMedicine 40 (2019) 446–456]
por: Tan, Wenliang, et al.
Publicado: (2022)

miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression
por: Chen, Xianqing, et al.
Publicado: (2019)

Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
por: Tan, Wenliang, et al.
Publicado: (2017)

miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
por: Tan, Wenliang, et al.
Publicado: (2021)

Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection
por: Zhu, Sicong, et al.
Publicado: (2018)

High Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma
por: Huang, Xuelian, et al.
Publicado: (2022)

GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2022)

Low expression of long noncoding RNA CTC‐297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma
por: Zhu, Sicong, et al.
Publicado: (2019)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma
por: Wang, Qingbin, et al.
Publicado: (2023)

SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression
por: Ma, Xiaowu, et al.
Publicado: (2022)

Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma
por: Zhuang, Hongkai, et al.
Publicado: (2022)

CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway
por: Yang, Lei, et al.
Publicado: (2022)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

A FITM1-Related Methylation Signature Predicts the Prognosis of Patients With Non-Viral Hepatocellular Carcinoma
por: Chen, Jie, et al.
Publicado: (2020)

Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
por: Chen, Chih-Ta, et al.
Publicado: (2020)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
por: Pietrobono, Silvia, et al.
Publicado: (2021)

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
por: Chen, Zibo, et al.
Publicado: (2022)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells
por: Tang, Shuyao, et al.
Publicado: (2016)

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma
por: Shi, Hewen, et al.
Publicado: (2023)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms
por: Chen, Jiang, et al.
Publicado: (2020)

Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells
por: Huang, Zejian, et al.
Publicado: (2017)

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
por: Tang, Weiwei, et al.
Publicado: (2020)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
por: Chen, Yunching, et al.
Publicado: (2017)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
por: He, Wubin, et al.
Publicado: (2021)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
por: Ye, Sheng-Long, et al.
Publicado: (2018)

Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway
por: Qi, Feng, et al.
Publicado: (2021)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma
por: Suk, Fat-Moon, et al.
Publicado: (2019)

Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides
por: To, Jeffrey C., et al.
Publicado: (2023)

TNF-α-1031T/C gene polymorphism as a predictor of malnutrition in patients with gastric cancer
por: Fu, Liang, et al.
Publicado: (2023)

Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na(+)/K(+)-ATPase activity and hypoxia-inducible pathways
por: Jiang, Wenjing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sc1ie6blbb878b5q7dgqrfrgb1